Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma - PubMed (original) (raw)
Comment
Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma
Umberto Cillo et al. Ann Surg. 2004 Feb.
Abstract
Objective: To determine the long-term results of liver transplantation for well- or moderately differentiated hepatocellular carcinoma (HCC).
Summary background data: HCC patient selection for liver transplantation remains controversial, and deciding exclusively on the strength of criteria such as number and size of nodules appears prognostically inaccurate.
Methods: Since 1991, preoperative tumor grading has been used at our center to establish whether a patient with HCC is fit for transplantation. Poorly differentiated HCC cases were excluded, while size and number of nodules were not considered as absolute selection criteria. Thirty-three patients with moderately or well-differentiated HCC were prospectively studied after liver transplantation. A group of 15 patients with incidental HCC transplanted during the same period were also evaluated and compared with the 33 patients with preoperatively diagnosed HCC.
Results: On histologic examination, 38% of the entire group of 48 patients did not meet the "Milan criteria" and 42% were pTNM stages III and IV. The median follow-up was 44 months. The 5-year actuarial survival rate was 75% and recurrence-free survival was 92%. HCC recurred in only 3 patients (6%). The only histomorphologic variable differing significantly between incidental and nonincidental HCC was nodule size. The timing of diagnosis (incidental vs. nonincidental HCC), the Milan criteria, and the TNM stage revealed no statistically significant impact on overall and recurrence-free survival rates.
Conclusions: The routine pre-orthotopic liver transplantation tumor grading may represent a valid tool in the selection of unresectable HCC patients for transplantation.
Figures
FIGURE 1. Overall (A) and recurrence-free (B) survival curves after OLT in the 48 patients enrolled in the study. Standard errors at 3 years are 7% and 4.6%, respectively; 95% confidence intervals are represented by dashed lines.
FIGURE 2. Comparison between overall survival curves of HCC-related OLT (iHCC and pkHCC) versus OLT for nonmalignant disease. The log-rank test found no statistically significant differences.
FIGURE 3. A: Comparison between recurrence-free survival curves for iHCC versus pkHCC cases. The log-rank test found no statistically significant differences. B: Comparisons between recurrence-free survival curves for HCC that did versus did not meet the Milan criteria after histologic assessment. The log-rank test found no statistically significant differences.
Comment in
- Liver transplantation for hepatocellular carcinoma: need for a new patient selection strategy.
Pawlik TM, Abdalla EK, Vauthey JN. Pawlik TM, et al. Ann Surg. 2004 Nov;240(5):923-4; author reply 924-5. doi: 10.1097/01.sla.0000143896.65218.e3. Ann Surg. 2004. PMID: 15492579 Free PMC article. No abstract available.
Comment on
- Challenging choices: liver transplantation for hepatocellular carcinoma.
Knechtle SJ. Knechtle SJ. Ann Surg. 2004 Feb;239(2):160-1. doi: 10.1097/01.sla.0000109169.72607.50. Ann Surg. 2004. PMID: 14745322 Free PMC article. No abstract available.
Similar articles
- Predictors of long-term survival after liver transplantation for hepatocellular carcinoma.
Zavaglia C, De Carlis L, Alberti AB, Minola E, Belli LS, Slim AO, Airoldi A, Giacomoni A, Rondinara G, Tinelli C, Forti D, Pinzello G. Zavaglia C, et al. Am J Gastroenterol. 2005 Dec;100(12):2708-16. doi: 10.1111/j.1572-0241.2005.00289.x. Am J Gastroenterol. 2005. PMID: 16393224 - Hepatocellular carcinoma recurrence among liver transplant recipients within the Milan criteria.
Felga G, Evangelista AS, Salvalaggio PR, Curvelo LA, Della Guardia B, Almeida MD, Afonso RC, Ferraz-Neto BH. Felga G, et al. Transplant Proc. 2012 Oct;44(8):2459-61. doi: 10.1016/j.transproceed.2012.07.004. Transplant Proc. 2012. PMID: 23026620 - Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma.
Piardi T, Gheza F, Ellero B, Woehl-Jaegle ML, Ntourakis D, Cantu M, Marzano E, Audet M, Wolf P, Pessaux P. Piardi T, et al. Ann Surg Oncol. 2012 Jun;19(6):2020-6. doi: 10.1245/s10434-011-2170-9. Epub 2011 Dec 17. Ann Surg Oncol. 2012. PMID: 22179632 - Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma.
Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N. Samuel D, et al. Liver Transpl. 2011 Oct;17 Suppl 2:S6-13. doi: 10.1002/lt.22423. Liver Transpl. 2011. PMID: 21858912 Review. - Liver transplantation for hepatocellular carcinoma: past, present, and future.
Asham EH, Boktour M, Ghobrial RM. Asham EH, et al. Clin Transpl. 2012:173-83. Clin Transpl. 2012. PMID: 23721020 Review.
Cited by
- Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma.
Rastogi A. Rastogi A. World J Gastroenterol. 2018 Sep 21;24(35):4000-4013. doi: 10.3748/wjg.v24.i35.4000. World J Gastroenterol. 2018. PMID: 30254404 Free PMC article. Review. - Solitary pulmonary metastasis arising thirteen years after liver transplantation for HBV-related hepatocellular carcinoma.
Viola C, Asselah T, Samuel D, Durand F, Boudjema H, Valla D, Marcellin P. Viola C, et al. World J Gastroenterol. 2006 Aug 14;12(30):4911-3. doi: 10.3748/wjg.v12.i30.4911. World J Gastroenterol. 2006. PMID: 16937481 Free PMC article. - Role of Allelic Imbalance in Predicting Hepatocellular Carcinoma (HCC) Recurrence Risk After Liver Transplant.
Pagano D, Barbera F, Conaldi PG, Seidita A, Di Francesco F, Di Carlo D, Bàrbara M, Tuzzolino F, Luca A, Gruttadauria S. Pagano D, et al. Ann Transplant. 2019 Apr 24;24:223-233. doi: 10.12659/AOT.913692. Ann Transplant. 2019. PMID: 31015392 Free PMC article. - Diagnostic Value of Preoperative Needle Biopsy for Tumor Grading Assessment in Hepatocellular Carcinoma.
Wang L, Wang J, Zhang X, Li J, Wei X, Cheng J, Ling Q, Xie H, Zhou L, Xu X, Zheng S. Wang L, et al. PLoS One. 2015 Dec 14;10(12):e0144216. doi: 10.1371/journal.pone.0144216. eCollection 2015. PLoS One. 2015. PMID: 26658912 Free PMC article. - Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA.
El-Fattah MA. El-Fattah MA. Indian J Gastroenterol. 2017 Mar;36(2):117-125. doi: 10.1007/s12664-017-0732-x. Epub 2017 Feb 14. Indian J Gastroenterol. 2017. PMID: 28194604
References
- Olthoff KM, Millis JM, Rosove MH, et al. Is liver transplantation justified for the treatment of hepatic malignancies? Arch Surg. 1990;125:1261–1268. - PubMed
- Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434–1440. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical